Israel’s Technion Institute has developed the technology to detect Parkinson’s disease through the patient’s breath. The scientists in charge have achieved an efficiency of about 81% of precision, almost the same achieved with magnetic resonances.

The device developed in the Technion and its applied software manages to detect the chemical signatures of several diseases including Parkinson’s, which already affects 10 million people worldwide. The early detection of Parkinson’s is of great importance to achieve treatments that favor the patient, although the disease is incurable.

The reduction in the early stages of Parkinson’s in the loss of neurotransmitters could mean a new paradigm in the treatment of the disease and neuroprotection therapies, and present new expectations very different from the current protocols based on available means. Another of the benefits of this project is the possibility of diagnosing patients who have not been previously medicated, that is, those who will face the diagnosis of Parkinson’s for the first time.

The Technion team, led by Prof. John Feinberg and Prf. Hossam Haick, has managed to assemble a multinational contingent dedicated to refining the device and its technique. They say early detection will definitely produce a more appropriate and efficient treatment.

Technically it may seem like chaos to the normal individual: 40 different sensors detect at a nano-level, different marker molecules that uncover the disease with a precision that eliminates the use of aggressive, invasive, uncomfortable and costly means. The method also promises to be faster and cheaper and would ultimately be used across the globe as a standard test for Parkinson’s.